AKT1 and lung carcinoma: These findings not only shed additional light on the molecular mechanisms that are activated by signalling through the PI3K/AKT pathway in lung epithelial cells, but also may contribute to identify previously unrecognised therapeutic targets in lung cancer driven by aberrant PI3K/AKT signaling.